Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Neoadjuvant Chemoradiotherapy Alone for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma (NICE 2): a Multi-center, Randomized Phase II Trial

NCT05043688 is registered in ClinicalTrials.gov with Zhigang Li as lead sponsor.

NCT NCT05043688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05043688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Neoadjuvant Chemoradiotherapy Alone for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma (NICE 2): a Multi-center, Randomized Phase II Trial
Lead sponsor
Zhigang Li
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 1, 2021
Completion date
December 31, 2030
Enrollment
426 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

resectable esophageal squamous cell carcinoma